AAA
BHVN

Affinity Asset Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Affinity Asset Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,500
Closed -$1.04M – 87
2021
Q3 		$1.04M Buy
+7,500
New +$936K 0.26% 57

Other funds holding BHVN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Affinity Asset Advisors's BHVN Position: Q4 2021 in Review

Affinity Asset Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2021, closing a stake of 7,500 shares — an estimated $1.04M sold.

Affinity Asset Advisors first reported a position in BHVN in Q3 2021 and held it in 1 quarter. The position peaked at $1.04M in Q3 2021. 284 funds tracked by Wall St. Rank hold BHVN as of Q4 2021.

  • Affinity Asset Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2021 after selling out during the quarter.
  • Affinity Asset Advisors sold 7,500 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2021, an estimated $1.04M.
  • Affinity Asset Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021 and held it in 1 quarter.
  • Affinity Asset Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.04M in Q3 2021.
  • 284 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2021.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.